Literature DB >> 35503578

Intravenous maintenance fluid therapy practice in the pediatric acute and critical care settings: a European and Middle Eastern survey.

Claire Morice1, Fahad Alsohime2,3, Huw Mayberry4, Lyvonne N Tume4,5, David Brossier6,7, Frederic V Valla5,8.   

Abstract

The ideal fluid for intravenous maintenance fluid therapy (IV-MFT) in acutely and critically ill children is controversial, and evidence-based clinical practice guidelines are lacking and current prescribing practices remain unknown. We aimed to describe the current practices in prescribing IV-MFT in the context of acute and critically ill children with regard to the amount, tonicity, composition, use of balanced fluids, and prescribing strategies in various clinical contexts. A cross-sectional electronic 27-item survey was emailed in April-May 2021 to pediatric critical care physicians across European and Middle East countries. The survey instrument was developed by an expert multi-professional panel within the European Society of Pediatric and Neonatal Intensive Care (ESPNIC). A total of 154 respondents from 35 European and Middle East countries participated (response rate 64%). Respondents were physicians in charge of acute or critically ill children. All respondents indicated they routinely use a predefined formula to prescribe the amount of IV-MFT and considered fluid balance monitoring very important in the management of acute and critically ill children. The use of balanced solution was preferred if there were altered serum sodium and chloride levels or metabolic acidosis. Just under half (42%, 65/153) of respondents believed balanced solutions should always be used. Respondents considered the use of isotonic IV solutions as important for acute and critically ill children. In terms of the indication and the composition of IV-MFT prescribed, responses were heterogeneous among centers. Almost 70% (107/154) respondents believed there was a gap between current practice and what they considered ideal IV-MFT due to a lack of guidelines and inadequate training of healthcare professionals.   Conclusions: Our study showed considerable variability in clinical prescribing practice of IV-MFT in acute pediatric settings across Europe and the Middle East. There is an urgent need to develop evidence-based guidelines for IV-MFT prescription in acute and critically ill children. What is Known: • The administration of maintenance intravenous fluid therapy is a standard of care for a lot of hospitalized children • Maintenance intravenous fluid therapy prescriptions are often based on Holliday and Segar's historical guidelines even if this practice has been associated with several complications. What is New: • This study provided information on the prescribing practice regarding fluid restriction, fluid tonicity, and balance. • This study showed considerable variability in clinical prescribing practice of intravenous maintenance fluid therapy across Europe and the Middle East.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Adolescent; Balanced solutions; Child; In-hospital; Intravenous fluids; Neonate

Mesh:

Substances:

Year:  2022        PMID: 35503578     DOI: 10.1007/s00431-022-04467-y

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.860


  3 in total

1.  Sodium balance, not fluid balance, is associated with respiratory dysfunction in mechanically ventilated patients: a prospective, multicentre study.

Authors:  Shailesh Bihari; Sandra L Peake; Shivesh Prakash; Manoj Saxena; Victoria Campbell; Andrew Bersten
Journal:  Crit Care Resusc       Date:  2015-03       Impact factor: 2.159

2.  Hyponatremia and death in Healthy children From plain dextrose and Hypotonic Saline Solutions after Surgery.

Authors:  Matthew Grissinger
Journal:  P T       Date:  2013-07

Review 3.  Balanced Crystalloid Solutions.

Authors:  Matthew W Semler; John A Kellum
Journal:  Am J Respir Crit Care Med       Date:  2019-04-15       Impact factor: 21.405

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.